Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Olmesartan Medoxomil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 known ✓ | P30556 | 11/20 | 0.79 |
| ▸ | AGTR2 | P50052 | 12/20 | 0.79 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.79 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.79 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.79 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.79 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.79 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.79 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.79 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2844872 | 0.96 | AGTR2 (0.73) | AGTR2AGTR1ABCC3ABCC4ABCB11 | |
| SCHEMBL15132375 | 0.95 | AGTR2 (0.72) | AGTR2AGTR1ABCC3ABCC4ABCB11 | |
| SCHEMBL6857515 | 0.95 | AGTR2 (0.71) | AGTR2AGTR1ABCC3ABCC4ABCB11 | |
| SCHEMBL7302860 | 0.94 | AGTR2 (0.71) | AGTR2AGTR1ABCC3ABCC4ABCB11 | |
| SCHEMBL4019176 | 0.94 | AGTR1 (0.70) | AGTR2AGTR1ABCC3ABCC4ABCB11 | |
| SCHEMBL2626709 | 0.93 | AGTR2 (0.69) | AGTR2AGTR1ABCC3ABCC4ABCB11 | |
| SCHEMBL6434240 | 0.93 | AGTR2 (0.70) | AGTR2AGTR1ABCC3ABCC4ABCB11 | |
| SCHEMBL7886557 | 0.93 | AGTR2 (0.68) | AGTR2AGTR1ABCC3ABCC4ABCB11 | |
| SCHEMBL7883447 | 0.93 | AGTR2 (0.68) | AGTR2AGTR1ABCC3ABCC4ABCB11 | |
| SCHEMBL8243357 | 0.91 | AGTR2 (0.65) | AGTR2AGTR1ABCC3ABCC4ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 249 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321046-A1 | PHARMACEUTICAL COMPOSITION OF SINGLE DOSAGE FORM FOR TREATING OR PREVENTING HYPERTENSION AND HYPERLIPIDEMIA | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2023-10-12 | — | — | US | claimed |
| EP-4205730-A1 | PHARMACEUTICAL COMPOSITION OF SINGLE DOSAGE FORM FOR TREATING OR PREVENTING HYPERTENSION AND HYPERLIPIDEMIA | Daewoong Pharmaceutical Co., Ltd. (KR) | 2023-07-05 | — | — | EP | claimed |
| EP-3045174-A1 | MEDICINE FOR PREVENTION OF AND TREATMENT FOR ARTERIOSCLEROSIS AND HYPERTENSION | Daiichi Sankyo Company, Limited (JP) | 2016-07-20 | — | — | EP | claimed |
| EP-2517728-B1 | Olmesartan medoxomil for preventing or treating angiogenic eye diseases | DAIICHI SANKYO CO LTD (JP) | 2015-01-28 | — | — | EP | claimed |
| EP-2174666-B1 | MEDICINAL AGENT FOR TREATMENT OF AMYLOID BETA-INDUCED CEREBRAL CIRCULATION OR CEREBRAL BLOOD FLOW DISORDERS | DAIICHI SANKYO CO LTD (JP) | 2013-12-18 | — | — | EP | claimed |
| US-20120302614-A1 | METHOD FOR IMPROVING CEREBRAL CIRCULATION OR TREATING A CEREBRAL BLOOD FLOW DISORDER | OSAKA UNIVERSITY (JP) | 2012-11-29 | — | — | US | claimed |
| EP-2517728-A1 | Drug for preventing or treating angiogenic eye diseases | Daiichi Sankyo Company, Limited (JP) | 2012-10-31 | — | — | EP | claimed |
| EP-2334668-A1 | PROCESS FOR PREPARING OLMESARTAN MEDOXOMIL INTERMEDIATE | Krka Tovarna Zdravil, D.D., Novo Mesto (SI) | 2011-06-22 | — | — | EP | claimed |
| US-20100130567-A1 | MEDICAL AGENT FOR PREVENTION OR TREATMENT OF ALZHEIMER 'S DISEASE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-05-27 | — | — | US | claimed |
| EP-2174666-A1 | MEDICINAL AGENT FOR PREVENTION OR TREATMENT OF ALZHEIMER'S DISEASE | Daiichi Sankyo Company, Limited (JP) | 2010-04-14 | — | — | EP | claimed |
| EP-1872783-A1 | THERAPEUTIC AGENT FOR CORNEAL/CONJUNCTIVAL DISORDER | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-01-02 | — | — | EP | claimed |
| US-20070203211-A1 | Drug for preventing or treating angiogenic eye diseases | SANKYO COMPANY, LIMITED (JP) | 2007-08-30 | — | — | US | claimed |
| US-20060252806-A1 | synergistic use of angiotensin II receptor antagonist like (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]imidazol-5-carboxylate with the calcium channel blockers; calcium channel blockers containing 1,4-dihydropyridine group | SANKYO COMPANY LIMITED (JP) | 2006-11-09 | — | — | US | claimed |
| US-20060252805-A1 | Medicine for prevention of and treatment for arteriosclerosis and hypertension | SANKYO COMPANY LIMITED (JP) | 2006-11-09 | — | — | US | claimed |
| US-20060009502-A1 | Medicine for prevention of and treatment for arteriosclerosis and hypertension | SANKYO COMPANY, LIMITED (JP) | 2006-01-12 | — | — | US | claimed |
| EP-1614428-A1 | DRUG FOR PREVENTING OR TREATING ANGIOGENIC EYE DISEASES | Sankyo Company, Limited (JP) | 2006-01-11 | — | — | EP | claimed |
| EP-1604664-A1 | MEDICINE FOR PREVENTION OF AND TREATMENT FOR ARTERIOSCLEROSIS AND HYPERTENSION | Sankyo Company, Limited (JP) | 2005-12-14 | — | — | EP | claimed |
| EP-0503785-B1 | 1-Biphenylimidazole derivatives, their preparation and their therapeutic use | SANKYO CO (JP) | 2001-04-25 | — | — | EP | claimed |
| US-5616599-A | HYPOTENSIVE AGENTS FOR CARDIOVASCULAR DISORDER | SANKYO COMPANY, LIMITED (JP) | 1997-04-01 | — | — | US | claimed |
| EP-0503785-A1 | 1-Biphenylimidazole derivatives, their preparation and their therapeutic use | Sankyo Company Limited (JP) | 1992-09-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130567-A1 | MEDICAL AGENT FOR PREVENTION OR TREATMENT OF ALZHEIMER 'S DISEASE | AGTR1, AGTR2, ACE | AGTR1 1/4885AGTR2 2/4885ABCC3 1034/4885 |
| US-20060252805-A1 | Medicine for prevention of and treatment for arteriosclerosis and hypertension | AGTR1, AGTR2, EDNRB | AGTR1 1/4885AGTR2 2/4885ABCC3 754/4885 |
| US-20120302614-A1 | METHOD FOR IMPROVING CEREBRAL CIRCULATION OR TREATING A CEREBRAL BLOOD FLOW DISORDER | AGTR2, AGTR1, BDKRB2 | AGTR1 2/4885AGTR2 1/4885ABCC3 1984/4885 |
| US-20060252806-A1 | synergistic use of angiotensin II receptor antagonist like (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]imidazol-5-carboxylate with the calcium channel blockers; calcium channel blockers containing 1,4-dihydropyridine group | AGTR1, AGTR2, CACNA1D | AGTR1 1/4885AGTR2 2/4885ABCC3 2182/4885 |
| US-20060009502-A1 | Medicine for prevention of and treatment for arteriosclerosis and hypertension | AGTR2, AGTR1, REN | AGTR1 2/4885AGTR2 1/4885ABCC3 1064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.